IDEAS home Printed from https://ideas.repec.org/a/eee/jbrese/v97y2019icp281-290.html

Effects of price cap regulation on the pharmaceutical supply chain

Author

Listed:
  • Chen, Xu
  • Yang, Huan
  • Wang, Xiaojun

Abstract

This paper considers a pharmaceutical supply chain composed of one pharmaceutical manufacturer and one pharmacy. We investigate how price cap regulation affects pharmaceutical firms' pricing decisions. We also evaluate the economic and social performance of the pharmaceutical supply chain and assess the risks associated with price cap regulation. The derived equilibriums under different price cap regulations, including retailer price cap regulation, manufacturer price cap regulation and linkage price cap regulation, are compared to that without regulation. Our results show that one-sided price cap regulation will damage the economic performance of the regulated firm, whereas the unregulated firm may gain a financial advantage. The regulation may increase the risk of a supply shortage if pharmaceutical firms cannot cope with the financial loss. In contrast, linkage price cap regulation can be an effective policy for improving both the economic and social performance of the pharmaceutical supply chain.

Suggested Citation

  • Chen, Xu & Yang, Huan & Wang, Xiaojun, 2019. "Effects of price cap regulation on the pharmaceutical supply chain," Journal of Business Research, Elsevier, vol. 97(C), pages 281-290.
    • Handle: RePEc:eee:jbrese:v:97:y:2019:i:c:p:281-290
    DOI: 10.1016/j.jbusres.2018.01.030
    as

    Download full text from publisher

    File URL: http://www.sciencedirect.com/science/article/pii/S0148296318300298
    Download Restriction: Full text for ScienceDirect subscribers only
    File URL: https://libkey.io/10.1016/j.jbusres.2018.01.030?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to

    for a different version of it.

    References listed on IDEAS

    as
    1. Chen, Xu & Wang, Xiaojun, 2016. "Effects of carbon emission reduction policies on transportation mode selections with stochastic demand," Transportation Research Part E: Logistics and Transportation Review, Elsevier, vol. 90(C), pages 196-205.
    2. Brekke, Kurt R. & Konigbauer, Ingrid & Straume, Odd Rune, 2007. "Reference pricing of pharmaceuticals," Journal of Health Economics, Elsevier, vol. 26(3), pages 613-642, May.
    3. Bardey, D. & Bommier, A. & Jullien, B., 2010. "Retail price regulation and innovation: Reference pricing in the pharmaceutical industry," Journal of Health Economics, Elsevier, vol. 29(2), pages 303-316, March.
    4. Amankwah-Amoah, Joseph, 2016. "An integrative process model of organisational failure," Journal of Business Research, Elsevier, vol. 69(9), pages 3388-3397.
    5. Morgan, Steve & Grootendorst, Paul & Lexchin, Joel & Cunningham, Colleen & Greyson, Devon, 2011. "The cost of drug development: A systematic review," Health Policy, Elsevier, vol. 100(1), pages 4-17, April.
    6. DiMasi, Joseph A. & Grabowski, Henry G. & Hansen, Ronald W., 2016. "Innovation in the pharmaceutical industry: New estimates of R&D costs," Journal of Health Economics, Elsevier, vol. 47(C), pages 20-33.
    7. Hatem Elleuch & Wafik Hachicha & Habib Chabchoub, 2014. "A combined approach for supply chain risk management: description and application to a real hospital pharmaceutical case study," Journal of Risk Research, Taylor & Francis Journals, vol. 17(5), pages 641-663, May.
    8. Dobrzykowski, David & Saboori Deilami, Vafa & Hong, Paul & Kim, Seung-Chul, 2014. "A structured analysis of operations and supply chain management research in healthcare (1982–2011)," International Journal of Production Economics, Elsevier, vol. 147(PB), pages 514-530.
    9. Xu Chen & Xiaojun Wang & Xinkuang Jiang, 2016. "The impact of power structure on the retail service supply chain with an O2O mixed channel," Journal of the Operational Research Society, Palgrave Macmillan;The OR Society, vol. 67(2), pages 294-301, February.
    10. Baron, David P & Myerson, Roger B, 1982. "Regulating a Monopolist with Unknown Costs," Econometrica, Econometric Society, vol. 50(4), pages 911-930, July.
    11. Jin, Yannan & Wang, Sujuan & Hu, Qiying, 2015. "Contract type and decision right of sales promotion in supply chain management with a capital constrained retailer," European Journal of Operational Research, Elsevier, vol. 240(2), pages 415-424.
    12. Brekke, Kurt R. & Grasdal, Astrid L. & Holms, Tor Helge, 2009. "Regulation and pricing of pharmaceuticals: Reference pricing or price cap regulation?," European Economic Review, Elsevier, vol. 53(2), pages 170-185, February.
    13. Binzhen Wu & Qiong Zhang & Xue Qiao, 2015. "Effects of pharmaceutical price regulation: China's evidence between 1997 and 2008," Journal of the Asia Pacific Economy, Taylor & Francis Journals, vol. 20(2), pages 290-329, April.
    14. Håkonsen, Helle & Horn, Anne Marie & Toverud, Else-Lydia, 2009. "Price control as a strategy for pharmaceutical cost containment--What has been achieved in Norway in the period 1994-2004?," Health Policy, Elsevier, vol. 90(2-3), pages 277-285, May.
    15. Patricia M. Danzon & Andrew W. Mulcahy & Adrian K. Towse, 2015. "Pharmaceutical Pricing in Emerging Markets: Effects of Income, Competition, and Procurement," Health Economics, John Wiley & Sons, Ltd., vol. 24(2), pages 238-252, February.
    16. Chong Wang & Xu Chen, 2017. "Option pricing and coordination in the fresh produce supply chain with portfolio contracts," Annals of Operations Research, Springer, vol. 248(1), pages 471-491, January.
    17. Chen, Xu & Wang, Xiaojun & Chan, Hing Kai, 2017. "Manufacturer and retailer coordination for environmental and economic competitiveness: A power perspective," Transportation Research Part E: Logistics and Transportation Review, Elsevier, vol. 97(C), pages 268-281.
    18. Hui Zhao & Chuanhui Xiong & Srinagesh Gavirneni & Adam Fein, 2012. "Fee-for-Service Contracts in Pharmaceutical Distribution Supply Chains: Design, Analysis, and Management," Manufacturing & Service Operations Management, INFORMS, vol. 14(4), pages 685-699, October.
    19. Raventós, Pedro & Zolezzi, Sandro, 2015. "Electronic tendering of pharmaceuticals and medical devices in Chile," Journal of Business Research, Elsevier, vol. 68(12), pages 2569-2578.
    20. Pugliese, Amedeo & Minichilli, Alessandro & Zattoni, Alessandro, 2014. "Integrating agency and resource dependence theory: Firm profitability, industry regulation, and board task performance," Journal of Business Research, Elsevier, vol. 67(6), pages 1189-1200.
    21. Selva, Guillermo, 2016. "Ricardo Palma Clinic," Journal of Business Research, Elsevier, vol. 69(9), pages 3892-3899.
    22. Prado, Andrea M. & Calderon, Daniel & Zúñiga, Roy, 2016. "Providing low-cost and high-quality medications to rural communities in developing countries: The case of Accion Medica Cristiana in Nicaragua," Journal of Business Research, Elsevier, vol. 69(9), pages 3910-3922.
    23. Chen, Xu & Wang, Xiaojun, 2015. "Free or bundled: Channel selection decisions under different power structures," Omega, Elsevier, vol. 53(C), pages 11-20.
    24. Cowan, Simon, 1998. "Welfare Consequences of Tight Price-Cap Regulation," Bulletin of Economic Research, Wiley Blackwell, vol. 50(2), pages 105-116, April.
    25. Luo, Zheng & Chen, Xu & Chen, Jing & Wang, Xiaojun, 2017. "Optimal pricing policies for differentiated brands under different supply chain power structures," European Journal of Operational Research, Elsevier, vol. 259(2), pages 437-451.
    26. Caijun Yang & Lina Wu & Wenfang Cai & Wenwen Zhu & Qian Shen & Zongjie Li & Yu Fang, 2016. "Current Situation, Determinants, and Solutions to Drug Shortages in Shaanxi Province, China: A Qualitative Study," PLOS ONE, Public Library of Science, vol. 11(10), pages 1-16, October.
    27. Hu, Jia & Mossialos, Elias, 2016. "Pharmaceutical pricing and reimbursement in China: When the whole is less than the sum of its parts," Health Policy, Elsevier, vol. 120(5), pages 519-534.
    28. Mats Ekelund & Björn Persson, 2003. "Pharmaceutical Pricing in a Regulated Market," The Review of Economics and Statistics, MIT Press, vol. 85(2), pages 298-306, May.
    29. Settanni, Ettore & Harrington, Tomás Seosamh & Srai, Jagjit Singh, 2017. "Pharmaceutical supply chain models: A synthesis from a systems view of operations research," Operations Research Perspectives, Elsevier, vol. 4(C), pages 74-95.
    30. Eunkyu Lee & Richard Staelin, 1997. "Vertical Strategic Interaction: Implications for Channel Pricing Strategy," Marketing Science, INFORMS, vol. 16(3), pages 185-207.
    31. Abbott, Thomas III, 1995. "Price regulation in the pharmaceutical industry: Prescription or placebo?," Journal of Health Economics, Elsevier, vol. 14(5), pages 551-565, December.
    32. Yu, Xuan & Li, Cheng & Shi, Yuhua & Yu, Min, 2010. "Pharmaceutical supply chain in China: Current issues and implications for health system reform," Health Policy, Elsevier, vol. 97(1), pages 8-15, September.
    33. Patricia Danzon & Adrian Towse & Jorge Mestre‐Ferrandiz, 2015. "Value‐Based Differential Pricing: Efficient Prices for Drugs in a Global Context," Health Economics, John Wiley & Sons, Ltd., vol. 24(3), pages 294-301, March.
    34. Yalabik, Baris & Fairchild, Richard J., 2011. "Customer, regulatory, and competitive pressure as drivers of environmental innovation," International Journal of Production Economics, Elsevier, vol. 131(2), pages 519-527, June.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Iacocca, Kathleen & Mahar, Stephen & Daniel Wright, P., 2022. "Strategic horizontal integration for drug cost reduction in the pharmaceutical supply chain," Omega, Elsevier, vol. 108(C).
    2. Ye, Yi & Nie, Jiajia & Guo, Qiang, 2025. "Economic analysis of energy procurement under price cap policy," Energy Economics, Elsevier, vol. 148(C).
    3. Lütkemeyer, Daniel & Heese, H. Sebastian & Wuttke, David A., 2021. "Overcoming inefficiencies in the development of personalized medicine," European Journal of Operational Research, Elsevier, vol. 290(1), pages 278-296.
    4. Tabaghdehi, Seyedeh Asieh H. & Hunter, John, 2020. "Long-run price behaviour in the gasoline market - The role of exogeneity," Journal of Business Research, Elsevier, vol. 116(C), pages 620-627.
    5. Fatemi, Maedeh S. & Ghodratnama, Ali & Tavakkoli-Moghaddam, Reza & Kaboli, Amin, 2022. "A multi-functional tri-objective mathematical model for the pharmaceutical supply chain considering congestion of drugs in factories," Research in Transportation Economics, Elsevier, vol. 92(C).
    6. Sharma, Rohit & Jain, Geetika & Paul, Justin, 2023. "Does the world need to change its vaccine distribution strategy for COVID-19?," Technovation, Elsevier, vol. 126(C).
    7. Xiaojie Yang & Li Liu & Yi Zheng & Xue Yang & Shanlin Sun, 2022. "Pricing Problems in the Pharmaceutical Supply Chain with Mixed Channel: A Power Perspective," Sustainability, MDPI, vol. 14(12), pages 1-20, June.
    8. Fatemeh Shekoohi Tolgari & Naeme Zarrinpoor, 2024. "A robust reverse pharmaceutical supply chain design considering perishability and sustainable development objectives," Annals of Operations Research, Springer, vol. 340(2), pages 981-1033, September.
    9. Lütkemeyer, Daniel & Heese, H. Sebastian & Wuttke, David A. & Gernert, Andreas K., 2022. "Pricing and market entry decisions in personalized medicine," International Journal of Production Economics, Elsevier, vol. 253(C).
    10. Xiang, Jie & He, Xiaozhou & Cheng, T.C.E., 2025. "Retailer hoarding in emergency situations: A game-theoretic analysis," Transportation Research Part E: Logistics and Transportation Review, Elsevier, vol. 200(C).
    11. Sun, Yajie & Wang, Fan & Zhuo, Xiaopo, 2024. "Blockchain adoption of pharmaceutical firms in a competitive market: Pricing, drug traceability and consumer awareness," International Journal of Production Economics, Elsevier, vol. 276(C).
    12. Syed Asif Raza, 2022. "A bibliometric analysis of pricing models in supply chain," Journal of Revenue and Pricing Management, Palgrave Macmillan, vol. 21(2), pages 228-251, April.
    13. Chen, Xu & Li, Shanshan & Wang, Xiaojun, 2020. "Evaluating the effects of quality regulations on the pharmaceutical supply chain," International Journal of Production Economics, Elsevier, vol. 230(C).
    14. Faghih-Roohi, Shahrzad & Akcay, Alp & Zhang, Yingqian & Shekarian, Ehsan & de Jong, Eelco, 2020. "A group risk assessment approach for the selection of pharmaceutical product shipping lanes," International Journal of Production Economics, Elsevier, vol. 229(C).
    15. Shabnam Rekabi & Ali Ghodratnama & Amir Azaron, 2022. "Designing pharmaceutical supply chain networks with perishable items considering congestion," Operational Research, Springer, vol. 22(4), pages 4159-4219, September.
    16. Zeinab Sazvar & Mahsa Zokaee & Reza Tavakkoli-Moghaddam & Samira Al-sadat Salari & Sina Nayeri, 2022. "Designing a sustainable closed-loop pharmaceutical supply chain in a competitive market considering demand uncertainty, manufacturer’s brand and waste management," Annals of Operations Research, Springer, vol. 315(2), pages 2057-2088, August.
    17. Li, Dong & Dong, Chuanwen, 2022. "Government regulations to mitigate the shortage of life-saving goods in the face of a pandemic," European Journal of Operational Research, Elsevier, vol. 301(3), pages 942-955.
    18. Saha, Esha & Rathore, Pradeep & Parida, Ratri & Rana, Nripendra P., 2022. "The interplay of emerging technologies in pharmaceutical supply chain performance: An empirical investigation for the rise of Pharma 4.0," Technological Forecasting and Social Change, Elsevier, vol. 181(C).

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Xiaojie Yang & Li Liu & Yi Zheng & Xue Yang & Shanlin Sun, 2022. "Pricing Problems in the Pharmaceutical Supply Chain with Mixed Channel: A Power Perspective," Sustainability, MDPI, vol. 14(12), pages 1-20, June.
    2. Chen, Xu & Li, Shanshan & Wang, Xiaojun, 2020. "Evaluating the effects of quality regulations on the pharmaceutical supply chain," International Journal of Production Economics, Elsevier, vol. 230(C).
    3. Chen, Xu & Wang, Xiaojun & Chan, Hing Kai, 2017. "Manufacturer and retailer coordination for environmental and economic competitiveness: A power perspective," Transportation Research Part E: Logistics and Transportation Review, Elsevier, vol. 97(C), pages 268-281.
    4. Wang, Chong & Chen, Jing & Chen, Xu, 2017. "Pricing and order decisions with option contracts in the presence of customer returns," International Journal of Production Economics, Elsevier, vol. 193(C), pages 422-436.
    5. Xu Chen & Huan Yang & Xiaojun Wang & Tsan-Ming Choi, 2025. "Optimal carbon tax design for achieving low carbon supply chains," Annals of Operations Research, Springer, vol. 349(2), pages 821-848, June.
    6. Xuyue Li, 2018. "Competing Retailers’ Environmental Investment: An Analysis under Different Power Structures," Energies, MDPI, vol. 11(10), pages 1-18, October.
    7. Chakraborty, Abhishek & Mandal, Prasenjit, 2021. "Channel efficiency and retailer tier dominance in a supply chain with a common manufacturer," European Journal of Operational Research, Elsevier, vol. 294(1), pages 100-121.
    8. Yanfen Mu & Feng Niu, 2022. "To Be or Not to Be? Strategic Analysis of Carbon Tax Guiding Manufacturers to Choose Low-Carbon Technology," Sustainability, MDPI, vol. 14(22), pages 1-16, November.
    9. Lin, Xiaogang & Chen, Danna & Zhou, Yong-Wu & Lin, Qiang, 2022. "Horizontal mergers in low carbon manufacturing," European Journal of Operational Research, Elsevier, vol. 297(1), pages 359-368.
    10. Niu, Wenju & Shen, Houcai & Zhang, Lianmin, 2022. "Impact of power structure on decarbonizing investment with uncertain innovation: A triple bottom line perspective," Transportation Research Part E: Logistics and Transportation Review, Elsevier, vol. 160(C).
    11. Matsui, Kenji, 2019. "A supply chain member should set its margin later if another member's cost is highly uncertain," European Journal of Operational Research, Elsevier, vol. 275(1), pages 127-138.
    12. Fernando Antoñanzas & Carmelo Juárez-Castelló & Roberto Rodríguez-Ibeas, 2011. "Innovation, loyalty and generic competition in pharmaceutical markets," SERIEs: Journal of the Spanish Economic Association, Springer;Spanish Economic Association, vol. 2(1), pages 75-95, March.
    13. Xiutian Shi & Xiaoli Zhang & Ciwei Dong & Subin Wen, 2018. "Economic Performance and Emission Reduction of Supply Chains in Different Power Structures: Perspective of Sustainable Investment," Energies, MDPI, vol. 11(4), pages 1-16, April.
    14. Brekke, Kurt R. & Canta, Chiara & Straume, Odd Rune, 2016. "Reference pricing with endogenous generic entry," Journal of Health Economics, Elsevier, vol. 50(C), pages 312-329.
    15. Chen, Xu & Luo, Zheng & Wang, Xiaojun, 2019. "Compete or cooperate: Intensity, dynamics, and optimal strategies," Omega, Elsevier, vol. 86(C), pages 76-86.
    16. Yu Xia & Jing Li & Zhongyang Zhang, 2023. "Effects of price cap regulation on pharmaceutical supply chain under the zero markup drug policy," Operational Research, Springer, vol. 23(4), pages 1-27, December.
    17. Zhang, Lina & Zhang, Yumeng & Chutani, Anshuman, 2022. "Riding the wave of fashion rental: The role of power structures and green advertising," Transportation Research Part E: Logistics and Transportation Review, Elsevier, vol. 168(C).
    18. Brekke, Kurt R. & Holmas, Tor Helge & Straume, Odd Rune, 2011. "Reference pricing, competition, and pharmaceutical expenditures: Theory and evidence from a natural experiment," Journal of Public Economics, Elsevier, vol. 95(7-8), pages 624-638, August.
    19. Chen, Xu & Wang, Xiaojun & Zhang, Dan & Yang, Mingfang, 2023. "Selling models for platforms under service-sensitive demand," Omega, Elsevier, vol. 115(C).
    20. Difei Geng & Kamal Saggi, 2023. "Optimal price regulations in international pharmaceutical markets with generic competition," World Scientific Book Chapters, in: Kamal Saggi (ed.), Technology Transfer, Foreign Direct Investment, and the Protection of Intellectual Property in the Global Economy, chapter 18, pages 415-433, World Scientific Publishing Co. Pte. Ltd..

    More about this item

    Keywords

    ;
    ;
    ;
    ;

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:eee:jbrese:v:97:y:2019:i:c:p:281-290. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Catherine Liu (email available below). General contact details of provider: http://www.elsevier.com/locate/jbusres .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.